Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$234.2MCash on Hand
36.3mo Cash Runway
Follow LXEO by emailGet an email when LXEO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about LXEO, unsubscribe in one click. Privacy
📣 What LXEO Says Is Next
2H 2027 · “Lexeo expects to initiate a pivotal study supporting accelerated approval in 2H 2027 Q3 2026 Earnings Update Today, Lexeo also reported financial results for the third quarter of 2026:”
Company press release, Nov 16, 2026 · SEC filing
1H 2027 · “Finalization of pivotal study design, statistical analysis plan and confirmatory evidence strategy expected in 1H 2027”
Company press release, Nov 16, 2026 · SEC filing
second half of 2027 · “The program remains on track to provide a topline data readout in the second half of 2027.”
Company press release, Sep 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 16, 2026 ·
Clinical trial Lexeo reported positive interim Phase I/II data for LX2020 in PKP2 arrhythmogenic cardiomyopathy, with an 80% mean NSVT reduction and 44% mean PVC reduction in high-dose cohorts (n=7). Form 8-K · SEC filing · Press release
Oct 29, 2026 ·
Financing Lexeo filed a shelf registration on Form S-3 for up to $300,000,000 in securities, including common stock, preferred stock, debt, warrants, subscription rights, purchase contracts and units. It carries forward $135,387,220.20 of unsold securities from a prior shelf. No offering price or amounts are set yet. Form S-3 · SEC filing
Sep 29, 2026 ·
Deal Lexeo completed its acquisition of Mantle for $5.3 million in cash, subject to adjustments, plus $3.0 million in Lexeo common stock. Up to $1.0 million in additional cash and up to $12.0 million in milestone payments may follow, none guaranteed. The stock was issued without registration. Form 8-K · SEC filing
Sep 22, 2026 ·
Deal Lexeo agreed to acquire private Mantle Therapeutics for $8.3 million upfront in cash and stock, plus up to $13.0 million in milestones, with closing expected in Q3 2026. Cash runway into 2028 is unchanged. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Earnings Reported Q2 2026 results: cash of $234.2 million, runway into 2028. Net loss was $25.9 million ($0.30 per share) versus $26.1 million a year earlier. R&D rose to $19.0 million. Dosing began in the LX2006 pivotal SUNRISE-FA 2 trial, and LX2020 received FDA RMAT designation. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 1/2 · Active Trial · Gene Therapy for ACM Due to a PKP2 Pathogenic Variant Registry primary completion date, not a results date
Jul 2027 · N/A · Recruiting · A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM Registry primary completion date, not a results date
Sep 2027 · N/A · Recruiting · Clinical Course Of Disease In Participants With FA-CM Registry primary completion date, not a results date
Nov 2028 · Phase 1 · Active Trial · Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease Registry primary completion date, not a results date
Sep 2029 · Phase 1/2 · Active Trial · Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia Registry primary completion date, not a results date
Aug 2030 · N/A · Enrolling · Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
LXEO holds $234.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $19.4M/quarter from operations,
an estimated runway of 36.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:27 · Moderate
Cash runway 29 months
ATM program on file since Mar 2025 +15
Shelf registration (S-3, Oct 2026) +10
Company says cash lasts into 2028 -5Treasury securities balances will be sufficient to fund our planned operating expenses and capital expenditure requirements into 2028.10-Q, Nov 2026
Share count +13% in a year +7
Recent financing filings on SEC EDGAR:
Oct 29, 2026 · Shelf registration, up to $300M · S-3
Share count 82,788,599 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full LXEO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LXEO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.